Semaglutide

The Uncomfortable Truth About Ozempic

Kurzgesagt – In a Nutshell

GLP-1 receptor agonist used for diabetes and obesity; long-acting variants lead to sustained appetite suppression; approved 2005 (diabetes) and 2014 (obesity).

How Sugar & Processed Foods Impact Your Health | Dr. Robert Lustig

Andrew Huberman

A GLP-1 analog that is effective for weight loss. Marketed as Ozempic (diabetes) and Wegovy (obesity).

188 - [AMA #30 Sneak Peek] How to Read and Understand Scientific Studies

Peter Attia MD

Mentioned as an example of a drug that had phase three trials for diabetes and is now undergoing phase four trials for obesity.

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A GLP-1 agonist used at high doses for weight loss, capable of reducing up to 10% body weight, and soon to be approved as a once-a-week injection for weight loss.

E150: Israel/Gaza escalating or not? EU censorship regime, Penn donors revolt, GLP-1 hype cycle

All-In Podcast

A GLP-1 receptor agonist drug, mentioned as a key component of the GLP-1 hype cycle, its effectiveness, side effects, and availability.

Dr. Peter Attia — Longevity Drugs, Alzheimer's Disease, and More

Tim Ferriss

A newer GLP-1 agonist, administered as a once-weekly injectable, showing remarkable 20% total body weight loss in overweight and obese individuals without diabetes, with potential transient nausea side effects.

Control Stress for Healthy Eating, Metabolism & Aging | Dr. Elissa Epel

Andrew Huberman

A class of drugs (agonists) that are effective in blocking hunger, especially in type 2 diabetics, and have gained recent popularity for weight loss.

The Science of Eating for Health, Fat Loss & Lean Muscle | Dr. Layne Norton

Andrew Huberman

An effective obesity treatment (GLP-1 mimetic) that acts as a powerful appetite suppressant, showing consistent average body weight loss of 15%. Also discussed as impacting both brain satiety centers and gut mechanosensors.

Exercise, Nutrition, Hormones for Vitality & Longevity | Dr. Peter Attia

Andrew Huberman

A glucagon-like peptide-1 agonist drug showing efficacy in weight loss, primarily through central hypothalamic effects on appetite, but can cause muscle loss and nausea.

252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting

Peter Attia MD

A GLP-1 agonist, mentioned as a drug for weight loss, with concerns about its use for minor weight loss and potential for muscle wasting if protein intake is not maintained.

How to Lose Fat with Science-Based Tools

Andrew Huberman

A prescription drug (GLP-1 analog) used for treating diabetes and obesity by increasing GLP-1, leading to significant weight loss and appetite reduction.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A GLP-1 drug approved for diabetes in 2017 (Ozempic) and weight loss (Wegovy), with a half-life of 7 days, leading to about 16% weight loss in trials.

How to Enhance Your Gut Microbiome for Brain & Overall Health

Andrew Huberman

A prescription drug that acts as a GLP-1 agonist, causing the release of more GLP-1, used to treat type II diabetes and reduce obesity.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

A GLP-1 agonist drug discussed for type 2 diabetes and obesity treatment, known by brand names Ozempic and Wegovy.

378 ‒ Women’s health & performance: how training, nutrition, & hormones interact across life stages

Peter Attia MD

Dr. Mehmet Oz on Fixing American Healthcare + Fraud | Live from Davos

All-In Podcast

Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Andrew Huberman

A GLP-1 agonist, known by brand names like Ozempic, used for type 2 diabetes and observed to cause weight loss.

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A GLP-1 receptor agonist available in injectable (oral formulation outcome data ongoing) form, approved for type 2 diabetes with cardiovascular outcome data, and a separate weight loss indication for obesity/overweight with risk factors.

212 - The Neuroscience of Obesity | Peter Attia, M.D. & Stephan Guyenet, Ph.D.

Peter Attia MD

A GLP-1 agonist, considered a safe and effective weight loss drug (e.g., as Wegovy) that can lead to significant weight loss, developed based on its mechanism of action, which includes increasing glucose-stimulated insulin secretion.

Diet & Nutrition for Mental Health | Dr. Chris Palmer

Andrew Huberman

A new class of drugs, initially for diabetes, now used for obesity, that impacts glucagon-like peptide-1 (GLP-1) pathways and aids weight loss.